The Federation of Kenya Pharmaceutical Manufacturers (FKPM) Delegation Meets Health Principal Secretary to Advance Local Pharmaceutical Manufacturing
Led by FKPM Chairman Vimal Shah, the delegation briefed the PS on their ongoing collaboration with the Division of Health Products and Technology. They presented findings from their Capacity Assessment Report and outlined strategies to boost domestic manufacturing of medical products.
"The government is prioritizing local manufacturing of health products," Dr. Oluga stated during the meeting. He emphasized that this initiative would help secure Kenya's supply of essential medical commodities.
The discussions focused on practical measures to develop Kenya's pharmaceutical manufacturing capacity, aligning with national health security objectives.
Distributed by APO Group on behalf of Ministry of Health, Kenya.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
11 hours ago
- Zawya
Uganda Strengthens Emergency Response Capacity Through African Volunteers Health Corps (AVoHC) - Strengthening and Utilizing Response Groups for Emergencies (SURGE) Training
With support from the Foreign, Commonwealth&Development Office (FCDO), the World Health Organization (WHO) is collaborating with the Government of Uganda to train 78 multidisciplinary One Health responders under the Strengthening and Utilizing Response Groups for Emergencies (SURGE) flagship programme. The AVoHC-SURGE training, a cornerstone of WHO's Emergency Preparedness and Response (EPR) strategy, is designed and led by WHO to equip countries with skilled, coordinated teams capable of deploying rapidly during health emergencies. In Uganda, WHO has convened and facilitated a diverse group of participants from multiple sectors, including health, agriculture, internal affairs, animal and fisheries industries, and the Uganda Defence Forces, reflecting the One Health approach to managing threats at the human–animal–environment interface. 'This training equips Uganda with the human capacity to respond quickly and decisively when emergencies occur. I commend the Ministry of Health for its leadership and commitment to strengthening emergency readiness,' said Dr Kasonde Mwinga, WHO Representative to Uganda. Through WHO's technical guidance, the training immerses participants in intensive sessions covering outbreak investigation, risk assessment, coordination, Gender based violence and Prevention and response of sexual exploitation, abuse and Harassment and rapid deployment operations. Practical simulations and scenario-based exercises replicate the realities of emergency response, ensuring participants are ready for coordinated action in the field. For many participants, the experience is transformative: 'I am honoured to attend the AVoHC-SURGE training by WHO Uganda. I gained critical skills in rapid response, coordination, and outbreak investigation, which empowers me to protect lives and build stronger, safer communities,' shared Dr Andama Adinani, one of the participants from the district local government. Others echoed similar sentiments, emphasizing how WHO's training builds technical capacity and strengthens networks across ministries and disciplines; connections that are critical to a cohesive national response when emergencies strike. The inclusion of responders from multiple ministries underscores the Government of Uganda's commitment to a multisectoral approach, supported by WHO's technical expertise. Emergencies such as Ebola, Marburg, cholera, and zoonotic diseases require coordination between human health, animal health, and environmental sectors. By strengthening this integrated response capacity, Uganda, through WHO's SURGE programme is better prepared to contain outbreaks before they escalate. 'Preparedness is an investment in the future. Every skill gained here, every relationship built across ministries, will help us act faster, smarter, and more effectively to protect Ugandans,' Lubwama Benard, Deputy Incident Commander, Ministry of Health. The AvoHC-SURGE initiative, supported by FCDO and implemented by WHO across Africa, has been rolled out in several countries. So far 27 out of the 30 countries have completed their trainings and the details of the trained teams have been uploaded in the responders database. As health threats grow increasingly complex, WHO's continued support to Uganda in strengthening its national response capacity offers a model for other countries in the region. With a trained cadre of 78 multidisciplinary responders ready for deployment, the country is poised to respond to public health emergencies with speed, precision, and confidence. Designed for impact, this training represents a best preparedness and readiness practice model to improve capacity to manage emergencies, disasters and other climate related emergencies on the African content. Distributed by APO Group on behalf of World Health Organization - Uganda.
Zawya
11 hours ago
- Zawya
Africans' health challenges: The case for homegrown biomedical research
For decades, Africa has relied on foreign medical research and to tackle its health crises, and the results no doubt raises major concerns. From malaria to cancer, the continent continues to bear the highest burden of diseases that have long solutions elsewhere, or worse, diseases that remain neglected globally. Yet, the solution has always been within reach: Africa needs its own biomedical research revolution. The current model, where data, diagnostics, and drugs are imported, isn't just unsustainable, it creates a dependency that limits rapid responses to emerging threats and leaves local health systems perpetually unprepared. We will therefore consider some factors* The Price of Scientific Dependence: Consider this: when COVID-19 struck, African scientists were some of the last to access vaccine technology, clinical trial resources, and manufacturing capacity. The continent had to wait, negotiate, and sometimes beg for access to solutions. Meanwhile, region-specific diseases, such as Lassa fever, sickle cell disease, and schistosomiasis, remain under-researched because they are not considered global priorities. If Africa does not research its diseases, who will? This dependence not only delays responses but perpetuates inequity. It means millions die waiting for solutions that a robust, well-funded African biomedical research ecosystem could have delivered more quickly and affordably. Local science, local solutions: Homegrown biomedical research is about more than national pride. It ensures that health interventions are tailored to local genetics, environments, and socio-cultural contexts. For example, cancer drugs developed in Western labs may not account for unique genetic mutations prevalent among African populations, limiting their efficacy. By investing in local research, Africa can develop treatments tailored to its people, based on real-world data gathered from its diverse populations and ecosystems. It can create affordable diagnostics, accessible drugs, and policies grounded in science. Governments, the private sector, and regional bodies must step up their efforts. Investing in research is investing in the future: in pandemic preparedness, in reducing healthcare costs, and in creating a knowledge economy that can compete globally. A call to action: The African Union's ambition for health sovereignty can only be realized with strong biomedical research. Policymakers must embed research in national health strategies, universities must prioritize translational science, and private investors must see research as an opportunity, not a risk. Public health without biomedical research is essentially a matter of guesswork. And guesswork is not a strategy for a continent battling the double burden of infectious and non-communicable diseases. Science revolution for health equity: In conclusion, if Africa is to control its health destiny, it must lead in its scientific research. The time for dependency is over. A continent of over a billion people deserves more than hand-me-down science. It's time to fund our labs, empower our scientists, and generate the solutions we've always needed, because no one will understand our diseases better than we do. Copyright © 2022 Nigerian Tribune Provided by SyndiGate Media Inc. (
Zawya
13 hours ago
- Zawya
AstraZeneca enters rare disease care in South Africa
AstraZeneca announced its entrance into rare disease care in South Africa at a launch event held at the Nelson Mandela Children's Hospital in Johannesburg. Its rare disease portfolio will bring treatments for complex conditions such as neurofibromatosis type 1 (NF1), paroxysmal nocturnal hemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS), and myasthenia gravis. The event included a panel discussion with experts from fields such as neuro-oncology, neurology, plastic surgery, and genetics. Panellists highlighted the vital need for coordinated, specialist-driven care and robust collaboration across public and private sectors to ensure that patients receive integrated support at every stage of their journey. Dr Nkuli Boikhutso, CEO of Nelson Mandela Children's Hospital, stated: 'We are honoured to be the site of this important milestone. "AstraZeneca's commitment to introducing new treatments for rare diseases offers hope for our young patients and aligns with our vision to provide world-class, specialised care for all children, regardless of their background.' Rare diseases Around the world, more than 400 million people are affected by over 10,000 known rare diseases, yet the vast majority of these conditions have no approved treatments. For many rare disease patients and their families, this often results in years of uncertainty, misdiagnosis, and limited or difficult treatment options. AstraZeneca is dedicated to transforming this landscape by introducing advanced therapies, supporting earlier and more accurate diagnoses, and fostering multidisciplinary collaboration. 'AstraZeneca's entry into the rare disease space in South Africa is both a proud and hopeful moment for us,' said Deepak Arora, African cluster country president at AstraZeneca. 'Building on decades of pioneering rare disease science, we are committed to expanding access to transformational medicines for conditions such as NF1, PNH. 'This marks a significant milestone in our mission to improve the lives of patients living with rare diseases, especially children who have had very few options until now.' AstraZeneca's rare disease strategy in Africa is anchored in three key priorities: accelerating access to vital medicines, driving innovation through research and development, and expanding its global reach to make meaningful change. All rights reserved. © 2022. Provided by SyndiGate Media Inc. (
